efile Public Visual Render
ObjectId: 202033179349305453 - Submission: 2020-11-12
TIN: 91-1157127
Form
990
Department of the Treasury
Internal Revenue Service
Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
Do not enter social security numbers on this form as it may be made public.
Go to
www.irs.gov/Form990
for instructions and the latest information.
OMB No. 1545-0047
20
19
Open to Public Inspection
A
For the 2019 calendar year, or tax year beginning
01-01-2019
, and ending
12-31-2019
B
Check if applicable:
Address change
Name change
Initial return
Final return/terminated
Amended return
Application pending
C
Name of organization
PATH
Doing business as
Number and street (or P.O. box if mail is not delivered to street address)
2201 WESTLAKE AVENUE NO 200
Room/suite
City or town, state or province, country, and ZIP or foreign postal code
SEATTLE
,
WA
98121
D Employer identification number
91-1157127
E Telephone number
(206) 285-3500
G
Gross receipts $
383,749,661
F
Name and address of principal officer:
BRIAN NEVILLE
2201 WESTLAKE AVENUE NO 200
SEATTLE
,
WA
98121
I
Tax-exempt status:
501(c)(3)
501(c)
(
)
(insert no.)
4947(a)(1)
or
527
J
Website:
WWW.PATH.ORG
H(a)
Is this a group return for
subordinates?
Yes
No
H(b)
Are all subordinates
included?
Yes
No
If "No," attach a list. (see instructions)
H(c)
Group exemption number
K
Form of organization:
Corporation
Trust
Association
Other
L
Year of formation:
1981
M
State of legal domicile:
WA
Part I
Summary
1
Briefly describe the organization’s mission or most significant activities:
SEE PART III, LINE 1.
2
Check this box
3
Number of voting members of the governing body (
Part VI
, line 1a)
........
3
15
4
Number of independent voting members of the governing body (
Part VI
, line 1b)
.....
4
15
5
Total number of individuals employed in calendar year 2019 (
Part V
, line 2a)
......
5
737
6
Total number of volunteers (estimate if necessary)
.............
6
0
7a
Total unrelated business revenue from
Part VIII
, column (C), line 12
........
7a
0
b
Net unrelated business taxable income from Form 990-T, line 39
.........
7b
0
Prior Year
Current Year
8
Contributions and grants (
Part VIII
, line 1h)
.........
305,315,221
286,808,545
9
Program service revenue (
Part VIII
, line 2g)
.........
1,500
2,038
10
Investment income (
Part VIII
, column (A), lines 3, 4, and 7d )
....
3,037,130
6,723,428
11
Other revenue (
Part VIII
, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)
980,560
836,870
12
Total revenue—add lines 8 through 11 (must equal
Part VIII
, column (A), line 12)
309,334,411
294,370,881
13
Grants and similar amounts paid (
Part IX
, column (A), lines 1–3 )
...
62,762,146
55,619,080
14
Benefits paid to or for members (
Part IX
, column (A), line 4)
.....
0
0
15
Salaries, other compensation, employee benefits (
Part IX
, column (A), lines 5–10)
139,545,675
131,590,498
16a
Professional fundraising fees (
Part IX
, column (A), line 11e)
.....
0
0
b
Total fundraising expenses (
Part IX
, column (D), line 25)
2,679,350
17
Other expenses (
Part IX
, column (A), lines 11a–11d, 11f–24e)
....
110,458,648
105,099,261
18
Total expenses. Add lines 13–17 (must equal
Part IX
, column (A), line 25)
312,766,469
292,308,839
19
Revenue less expenses. Subtract line 18 from line 12
.......
-3,432,058
2,062,042
Beginning of Current Year
End of Year
20
Total assets (
Part X
, line 16)
.............
237,501,233
243,064,155
21
Total liabilities (
Part X
, line 26)
.............
202,931,874
204,045,574
22
Net assets or fund balances. Subtract line 21 from line 20
.....
34,569,359
39,018,581
Part II
Signature Block
Sign Here
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.
2020-11-12
Signature of officer
Date
BRIAN NEVILLE
VP ACCOUNTING/FINANCIAL OPERATIONS
Type or print name and title
Paid Preparer Use Only
Print/Type preparer's name
Preparer's signature
Date
Check
if
self-employed
PTIN
P00288314
Firm's name
GELMAN ROSENBERG & FREEDMAN
Firm's EIN
52-1392008
Firm's address
4550 MONTGOMERY AVE SUITE 800N
BETHESDA
,
MD
208142930
Phone no.
(301) 951-9090
May the IRS discuss this return with the preparer shown above? (see instructions)
..........
Yes
No
For Paperwork Reduction Act Notice, see the separate instructions.
Cat. No. 11282Y
Form
990
(2019)
Page 2
Form 990 (2019)
Page
2
Part III
Statement of Program Service Accomplishments
Check if Schedule O contains a response or note to any line in this
Part III
..............
1
Briefly describe the organization’s mission:
PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O)
2
Did the organization undertake any significant program services during the year which were not listed on
the prior Form 990 or 990-EZ?
.....................
Yes
No
If "Yes," describe these new services on Schedule O.
3
Did the organization cease conducting, or make significant changes in how it conducts, any program
services?
...........................
Yes
No
If "Yes," describe these changes on Schedule O.
4
Describe the organization’s program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.
4a
(Code:
) (Expenses $
122,045,425
including grants of $
18,889,335
) (Revenue $
38
)
GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; AND NONCOMMUNICABLE DISEASES. THE DIVISION ALSO OVERSEES PATH'S WORK IN HEALTH SYSTEMS INNOVATION AND DELIVERY, AND MANAGES OUR COUNTRY OFFICES.(SEE SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASES:PATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. MORE THAN 200 PATH STAFF MEMBERS WORK ON MALARIA IN MORE THAN 30 COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DEVELOPING NEW STRATEGIES FOR ELIMINATION, DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. PATH-PIONEERED APPROACHES HAVE CONTRIBUTED TO REMARKABLE PROGRESS IN MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2019, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM, FUNDED BY THE BILL & MELINDA GATES FOUNDATION, CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA'S WORK INCLUDED SCALING UP PREVENTION AND TREATMENT; EVALUATING THE LATEST, MOST SENSITIVE DIAGNOSTIC TESTS; ESTABLISHING RAPID REPORTING SYSTEMS; AND CONTINUING TO SUPPORT POPULATION-WIDE, DRUG-BASED STRATEGIES SUCH AS MASS DRUG ADMINISTRATION. THROUGH OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO), FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE, PATH CONTINUED TO ASSIST THE GOVERNMENT OF ZAMBIA IN ITS EFFORTS TO ELIMINATE LOCAL MALARIA INFECTION AND DISEASE. IN 2019, PAMO PROVIDED TECHNICAL SUPPORT AND MENTORSHIP TO MORE THAN 1,200 HEALTH CARE WORKERS ACROSS FOUR PROVINCES TO IMPROVE THE QUALITY OF CARE. PAMO ALSO SUPPORTED THE DISTRIBUTION OF 115,416 INSECTICIDE-TREATED BEDNETS, ORGANIZED SOCIAL BEHAVIOR CHANGE ACTIVITIES (INCLUDING ENGAGING SCHOOLS AND PRINTING EDUCATIONAL MATERIALS), AND PROVIDED TECHNICAL AND MATERIAL SUPPORT FOR DATA QUALITY AUDITS IN HEALTH FACILITIES.ALSO IN ZAMBIA, THE VISUALIZE NO MALARIA PROJECT CONTINUED TO EXPAND. THIS PROJECT, A GROUNDBREAKING PARTNERSHIP BETWEEN PATH AND A COALITION OF TECHNOLOGY COMPANIES, EQUIPS HEALTH WORKERS AND OFFICIALS WITH REAL-TIME DATA VISUALIZATION TO SEE AND UNDERSTAND WHERE MALARIA IS APPEARING SO THEY CAN DEPLOY APPROPRIATE RESOURCES TO HALT ITS SPREAD.PATH CONTINUED TO DEVELOP AND EVALUATE NEW VECTOR CONTROL TOOLS IN 2019 WITH OUR PARTNERS IN VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND, WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. AND WE CONTINUED TO DEVELOP AND EVALUATE ATTRACTIVE TARGETED SUGAR BAITS, WHICH LURE MOSQUITOES TO A MEAL LACED WITH INSECTICIDE.IN 2019, THE MALARIA TEAM PARTNERED WITH PATH'S DIAGNOSTICS PROGRAM ON EVALUATIONS OF RAPID TESTS FOR MALARIA AS WELL AS CLINICAL STUDIES FOR POINT-OF-CARE TESTS TO DETECT AN ENZYME DEFICIENCY THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. PATH ALSO SUPPORTED THE COMMERCIALIZATION OF A DIAGNOSTICS ARRAY THAT CAN BE USED FOR MALARIA RESEARCH AND SURVEILLANCE. MOREOVER, WE LED A VALIDATION OF THE RESULTS OF MALARIA TESTS TAKEN DURING ANTENATAL CARE AS A ROUTINE MEASURE OF PARASITE PREVALENCE. FOR MORE INFORMATION, SEE THE DIAGNOSTICS SECTION. FINALLY, PATH WORKED WITH THE WORLD HEALTH ORGANIZATION (WHO) AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES.PATH'S EFFORTS TO ELIMINATE NEGLECTED TROPICAL DISEASES CONTINUED IN 2019 IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), WHERE WE WORKED WITH THE COUNTRY'S NATIONAL PROGRAM TO COMBAT HUMAN AFRICAN TRYPANOSOMIASIS (HAT, OR "SLEEPING SICKNESS"). WE SUPPORTED THE PROGRAM IN ACTIVE AND PASSIVE SCREENING FOR HAT CASES IN THREE KEY PROVINCES, AND WE ASSISTED THE LIVERPOOL SCHOOL OF TROPICAL MEDICINE TO DEPLOY CONTROL MEASURES FOR THE HAT VECTOR, TSETSE FLIES, USING THE "TINY TARGET" INNOVATIVE TECHNOLOGY. OUR WORK ALSO INCLUDED ADVOCACY TO RAISE AWARENESS OF HAT AT NATIONAL, PROVINCIAL, AND COMMUNITY LEVELS.IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE AT THE NATIONAL, STATE (UTTAR PRADESH), AND SUB-STATE LEVELS FOR ELIMINATION OF VISCERAL LEISHMANIASIS (KALA-AZAR) AND LYMPHATIC FILARIASIS (ELEPHANTIASIS). ADDITIONALLY, WE SUPPORTED INDIA'S VECTOR-BORNE DISEASE CONTROL PROGRAM AT THE STATE LEVEL TO COMBAT MALARIA, DENGUE, AND CHIKUNGUNYA.HIV AND TUBERCULOSIS:IN 2019, PATH CONTINUED CONTRIBUTIONS TO HIV PREVENTION AND EPIDEMIC CONTROL, AS WELL AS TUBERCULOSIS (TB) DETECTION AND CONTROL. OUR PROGRAMMING REACHED GENERAL POPULATIONS AS WELL AS THE KEY POPULATIONS OF ADOLESCENT GIRLS AND YOUNG WOMEN, PEOPLE WITH BOTH HIV AND TB, SEX WORKERS AND THEIR CLIENTS, MEN WHO HAVE SEX WITH MEN, PEOPLE WHO INJECT DRUGS, AND TRANSGENDER INDIVIDUALS. WE CONTINUED TO FIND AND DIAGNOSE, LINK TO TREATMENT, AND RETAIN PEOPLE ON TREATMENT AS WE ADVANCED PROGRAMMING ACROSS TECHNOLOGY AND SERVICE DELIVERY PLATFORMS. PATH SCALED DIFFERENTIATED PARTNER NOTIFICATION SERVICES, PROVIDING NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLHIV) WITH A SUITE OF OPTIONS FOR DISCLOSING THEIR POSITIVE STATUS AND PROVIDING HIV TESTING SERVICES TO THEIR PARTNERS AND FAMILIES. ACROSS OUR USAID-FUNDED PROGRAMS IN THE DRC, KENYA, UKRAINE, AND VIETNAM, WE TESTED MORE THAN 744,775 PEOPLE, INCLUDING 48,366 PARTNERS AND FAMILY MEMBERS OF PLHIV, AND ENROLLED MORE THAN 24,680 NEWLY DIAGNOSED PLHIV ON TREATMENT. AMBASSADOR DEBORAH BIRX HIGHLIGHTED OUR APPROACH AS THE MODEL THAT ALL COUNTRIES INVOLVED IN THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) SHOULD FOLLOW. OUR APPROACH ALSO LED TO A COLLABORATION WITH WHO TO DEVELOP GLOBAL GUIDELINES FOR SAFE PARTNER NOTIFICATION SERVICES FOR SEX WORKERS.IN THE DRC, PATH CONTINUED TO LEAD USAID-FUNDED EFFORTS TO CONTROL THE HIV EPIDEMIC. IN 2019, THIS WORK FOCUSED ON TWO HIGH-PREVALENCE PROVINCES UNDER THE INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA/LUALABA. PATH PROVIDED TECHNICAL ASSISTANCE TO 162 HEALTH FACILITIES, 18 HEALTH ZONES, AND FIVE NONGOVERNMENTAL ORGANIZATIONS (NGOS) TO INCREASE TARGETED TESTING EFFORTS, ENROLL ALL IDENTIFIED HIV-POSITIVE INDIVIDUALS ON TREATMENT, PROVIDE VIRAL LOAD TESTING, AND ROLL OUT DIFFERENTIATED CARE MODELS. PATH TESTED APPROXIMATELY 250,000 PEOPLE IN THE DRC, LINKED AROUND 14,000 NEWLY IDENTIFIED PLHIV TO TREATMENT, AND SUPPORTED A COHORT OF 40,000 PEOPLE TO CONTINUE TREATMENT. THROUGH THE AIDS, POPULATION, AND HEALTH INTEGRATED ASSISTANCE PROGRAM PLUS (APHIAPLUS) PROJECT IN 2019, PATH OPERATIONALIZED ELECTRONIC MEDICAL RECORDS SYSTEMS AT HEALTH FACILITIES IN WESTERN KENYA. BUILDING ON APHIAPLUS, WE ALSO LED THE USAID AND PEPFAR-FUNDED AFYA ZIWANI PROJECT. WE TESTED APPROXIMATELY 500,000 PEOPLE FOR HIV, LINKED AROUND 8,000 NEWLY IDENTIFIED PLHIV TO TREATMENT, AND SUPPORTED A COHORT OF 50,000 PEOPLE TO CONTINUE TREATMENT. TO DO THIS, WE DEVELOPED INNOVATIVE TOOLS FOR ELIGIBILITY SCREENING AND TRACKING MISSED APPOINTMENTS, AS WELL AS DATA DASHBOARDS. ALSO AS PART OF AFYA ZIWANI, PATH IMPLEMENTED THE DREAMS INITIATIVE, INTENSIFYING EFFORTS TO REACH NEARLY 80,000 ADOLESCENT GIRLS AND YOUNG WOMEN IN KENYA WITH INTERVENTIONS TO REDUCE THEIR VULNERABILITY TO HIV AND IMPROVE THEIR ACCESS TO SERVICES.
4b
(Code:
) (Expenses $
85,821,408
including grants of $
27,113,038
) (Revenue $
1,000
)
ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE. (CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS (CVIA) ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE.FOR EXAMPLE, IN 2019 PATH CONTINUED TO PARTNER WITH COUNTRIES TO EXPAND COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND CARRIED OUT A CAMPAIGN TO CELEBRATE PROGRESS TOWARD COMBATING JE. THE GOVERNMENT OF THE PHILIPPINES CONDUCTED JE VACCINATION CAMPAIGNS IN FOUR HIGH-RISK PROVINCES, WHICH PATH SUPPORTED THROUGH PLANNING, VACCINE PROVISION, AND COST-EFFECTIVENESS ANALYSIS. AS PATH'S 16-YEAR GLOBAL JE PARTNERSHIP PREPARED TO CLOSE, WE HOSTED A MEETING WITH KEY STAKEHOLDERS IN HANOI TO DISCUSS AND CAPTURE LESSONS LEARNED FOR COUNTRY VACCINATION PROGRAMS AND INTERNATIONAL VACCINE PARTNERS. PATH DEVELOPED AND LAUNCHED A WEB PAGE, INFOGRAPHIC, AND REPORT OUTLINING THESE LESSONS AND THE STORY OF JE VACCINATION EFFORTS. ALSO IN 2019, WE BEGAN A PIVOTAL, PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS VACCINE. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A VACCINE AGAINST MENINGOCOCCAL MENINGITIS SEROGROUP A THAT WAS LICENSED AND INTRODUCED IN 2010. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. THE VACCINE IS DESIGNED FOR USE IN AFRICA'S "MENINGITIS BELT" REGION AND, AS THE FIRST VACCINE TO TARGET SEROGROUP X, HAS THE POTENTIAL TO ELIMINATE MENINGITIS EPIDEMICS FROM THIS REGION. TO PREVENT MALARIA, PATH IS ACCELERATING THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. IN 2019, WE WORKED WITH WHO AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO BEGIN PILOT IMPLEMENTATION OF THE RTS,S VACCINE IN SELECTED AREAS OF THOSE COUNTRIES. WITH OUR PARTNERS, PATH CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. PILOT INTRODUCTION IN KENYA OF THE DELAYED FRACTIONAL-DOSE REGIMEN BEGAN IN 2019. ADDITIONALLY, WORK CONTINUED ON EFFORTS TO IDENTIFY IMMUNE CORRELATES OF PROTECTION FOR MALARIA VACCINES AND ON THE USE OF MONOCLONAL ANTIBODIES TO COMBAT MALARIA.IN 2019, THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE, HOUSED WITHIN CVIA, CONTINUED ITS ROLE AS A DIGITAL HUB FOR KEY INFORMATION AROUND PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE. IN PARTNERSHIP WITH PATH'S DRUG DEVELOPMENT PROGRAM, DEFEATDD LAUNCHED A CAMPAIGN TO PROMOTE THE ADDITION OF CO-PACKAGED ORAL REHYDRATION SOLUTION (ORS) AND ZINC TO THE WHO ESSENTIAL MEDICINES LIST FOR CHILDREN. DEFEATDD ALSO LAUNCHED A CAMPAIGN FOR WORLD TOILET DAY AROUND THE ROLE OF SANITATION IN HEALTH CARE ALONGSIDE VACCINES, NUTRITION, AND ACCESS TO MEDICINES. THROUGHOUT THE YEAR, DEFEATDD'S CHANNELS HELPED DISSEMINATE POLICY UPDATES AND RESEARCH ON THE PROJECTED HEALTH AND ECONOMIC IMPACTS OF NEW AND EXISTING ENTERIC VACCINES, INCLUDING ROTAVIRUS, CHOLERA, ENTEROTOXIGENIC ESCHERICHIA COLI, SHIGELLA, AND TYPHOID. DEFEATDD ALSO MAINTAINED, UPDATED, AND EXPANDED UPON ITS ONLINE STATE-OF-THE-FIELD REPORT, STOP THE CYCLE OF DIARRHEA. PATH CONDUCTED A PHASE 3 BRIDGING STUDY IN VIETNAM TO COMPARE A NEW LIQUID FORMULATION OF THE ROTAVIRUS VACCINE, ROTAVIN, WITH AN EARLIER LICENSED FROZEN FORMULATION, ROTAVIN-M1. WE CONDUCTED A PHASE 1 STUDY IN THE UNITED STATES TO ASSESS THE SAFETY OF A SUBUNIT SHIGELLA VACCINE CANDIDATE. ADDITIONALLY, PATH HELPED INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ENTERIC VACCINES, INCLUDING THE RECENTLY WHO-PREQUALIFIED ROTAVAC AND ROTASIIL ROTAVIRUS VACCINES.TO PREVENT TYPHOID, PATH, AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, IS WORKING TO ACCELERATE INTRODUCTION OF TYPHOID CONJUGATE VACCINES (TCVS) IN LOW-INCOME COUNTRIES. IN 2019, PATH SUPPORTED COUNTRIES THROUGHOUT THE VACCINE DECISION-MAKING AND INTRODUCTION PROCESS. WITH SUPPORT FROM PATH, PAKISTAN BECAME THE FIRST COUNTRY TO INTRODUCE TCV INTO ITS ROUTINE CHILDHOOD IMMUNIZATION PROGRAM. WE ALSO WORKED WITH THE GOVERNMENTS OF LIBERIA AND ZIMBABWE TO DETERMINE APPROPRIATE TCV INTRODUCTION STRATEGIES, SUCCESSFULLY APPLY FOR GAVI FINANCING, AND PREPARE FOR TCV INTRODUCTION. PATH CONTINUED TO CALL ATTENTION TO TYPHOID AND THE NEED FOR INTEGRATED SOLUTIONS THROUGH A RANGE OF ADVOCACY AND COMMUNICATIONS ACTIVITIES. PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. PATH IS SUPPORTING INVENTPRISE, A BIOTECHNOLOGY COMPANY, AS IT WORKS TO DEVELOP A MULTIVALENT, CONJUGATE VACCINE FOR LOW- AND MIDDLE-INCOME COUNTRIES. THE INTENDED RECIPIENTS ARE PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. ALSO IN 2019, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO ANALYZE EVIDENCE ON THE POTENTIAL FOR SINGLE-DOSE HPV VACCINATION. ALTHOUGH MANY COUNTRIES HAVE INTRODUCED HPV VACCINES INTO THEIR NATIONAL IMMUNIZATION SCHEDULES, SOME HAVE DELAYED INTRODUCTION BECAUSE OF FINANCIAL, LOGISTICAL, OR OTHER BARRIERS. FOR THESE COUNTRIES, A SINGLE-DOSE REGIMEN COULD ACCELERATE INTRODUCTION. PATH PROVIDES TECHNICAL ASSISTANCE TO GAVI-ELIGIBLE COUNTRIES IN PLANNING, IMPLEMENTING, AND EVALUATING NATIONAL HPV VACCINATION PROGRAMS AIMED AT VACCINATING YOUNG WOMEN. IN 2019, OUR GLOBAL TEAM AND PARTNERS ASSISTED THE GAMBIA, KENYA, AND THE SOLOMON ISLANDS WITH NATIONAL INTRODUCTIONS.
4c
(Code:
) (Expenses $
27,230,902
including grants of $
4,675,897
) (Revenue $
1,000
)
TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI) DIVISION IS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT MEDICAL DEVICES, HEALTH TECHNOLOGIES, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. TAMI ALSO MANAGES PATH'S WORK IN MARKET DYNAMICS AND DIGITAL AND DATA EXCELLENCE.(CONTINUED ON SCHEDULE O)MEDICAL DEVICES AND HEALTH TECHNOLOGIES:THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM WITHIN TAMI IS PATH'S INNOVATIVE PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, REFINE, INTRODUCE, AND SCALE AFFORDABLE TECHNOLOGIES TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.IN 2019, THE PROGRAM REACHED SEVERAL KEY MILESTONES; FOR EXAMPLE, THE ELLAVI UTERINE BALLOON TAMPONADE, A MEDICAL PRODUCT ADVANCED BY PATH TO MANAGE POSTPARTUM HEMORRHAGE, RECEIVED A CE MARK, AND THE FIRST SOLAR-POWERED "ENERGY HARVESTING CONTROL" VACCINE REFRIGERATORS, FOR WHICH PATH HAS BEEN CONDUCTING IN-COUNTRY ASSESSMENTS, PASSED PREQUALIFICATION TESTING IN SENEGAL FOR WHO PERFORMANCE, QUALITY, AND SAFETY APPROVAL. (ENERGY HARVESTING CONTROL ALLOWS EXTRA SOLAR POWER TO BE USED FOR OTHER PURPOSES AT A HEALTH FACILITY.) IN ADDITION, WE TRANSFERRED A FORMULATION AND LYOPHILIZATION PROCEDURE TO DERMBIONT FOR A TOPICAL GEL FORMULATION OF JANTHINOBACTERIUM LIVIDUM BACTERIA FOR TREATING FUNGAL INFECTIONS.PATH ALSO WORKED IN 2019 TO EVALUATE AND ADVANCE DEVICES FOR LONG-TERM ANTIRETROVIRAL DELIVERY OF PREP AND HIV TREATMENT. THESE DEVICES INCLUDE MICROARRAY PATCHES FOR TRANSDERMAL DELIVERY. STAFF PRODUCED 17 JOURNAL ARTICLES AND REPORTS ON RESEARCH FINDINGS, INCLUDING 2 FOR INACTIVATED POLIOVIRUS VACCINE: ONE EVALUATING THE TECHNICAL PRODUCT ATTRIBUTES OF AN ORAL ENTERIC VACCINE CURRENTLY UNDER DEVELOPMENT FOR INFANTS, THE OTHER EVALUATING THE COST PER CHILD VACCINATED WITH FULL VERSUS FRACTIONAL-DOSE VACCINE.DIAGNOSTICS:PATH ADVANCES EQUITABLE AND SUSTAINABLE ACCESS TO QUALITY-ASSURED, PURPOSE-DRIVEN DIAGNOSTICS FOR BETTER TESTING AND TREATMENT OF DISEASES IN LOW-RESOURCE SETTINGS.IN 2019, OUR PIONEERING WORK IN DIAGNOSTICS INCLUDED QUALIFYING, VALIDATING, EVALUATING, AND COMMERCIALIZING TESTS, REFERENCE ASSAYS, AND TOOLS; CONDUCTING PERFORMANCE EVALUATIONS AND CLINICAL TRIALS TO INFORM PATIENT CARE; AND PUBLISHING 20 PEER-REVIEWED JOURNAL ARTICLES.IN PARTNERSHIP WITH PATH'S MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM, THE DIAGNOSTICS TEAM INITIATED SIX CLINICAL STUDIES FOR POINT-OF-CARE TESTS FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY, A CONDITION THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. BY THE END OF 2019, WE HAD COMPLETED ENROLLMENT IN FIVE OF THE STUDIES. PATH ALSO SUPPORTED COMMERCIALIZATION OF THE QUANSYS Q-PLEX HUMAN MALARIA ARRAY, WHICH CAN BE USED FOR MALARIA RESEARCH AND SURVEILLANCE. ADDITIONALLY, WE EVALUATED THE PERFORMANCE OF SEVERAL MALARIA RAPID DIAGNOSTIC TESTS, WHICH CAN NOW PROCEED TO CLINICAL EVALUATIONS. THE DIAGNOSTICS TEAM ALSO ESTABLISHED A COMMUNITY OF PRACTICE FOR G6PD OPERATIONAL RESEARCH AND HOSTED THREE INFORMATION-SHARING WEBINARS. IN PARTNERSHIP WITH THE UNIVERSITY OF WASHINGTON, PATH DEVELOPED AND COMMERCIALIZED A BAG-MEDIATED FILTRATION SYSTEM FOR THE ENVIRONMENTAL SURVEILLANCE OF WILD POLIOVIRUS IN SEWAGE. THIS SYSTEM SIMPLIFIES COLLECTION OF THE MATERIAL TO BE TESTED. IN 2019, THE DIAGNOSTICS TEAM CELEBRATED THE LAUNCH OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY KIT THAT WE HELPED DEVELOP AND EVALUATE TO DETECT EXPOSURE TO ONCHOCERCA VOLVULUS, THE PARASITE THAT CAUSES ONCHOCERCIASIS (RIVER BLINDNESS). THE KIT SUPPORTS SEROLOGICAL SURVEILLANCE FOR RIVER BLINDNESS IN CONTROL AND ELIMINATION PROGRAMS IN AFRICA.PATH DIAGNOSTICS ALSO QUALIFIED AND VALIDATED A REFERENCE ASSAY FOR LIPOARABINOMANNAN (LAM), A VIRULENCE FACTOR ASSOCIATED WITH TB. THIS REFERENCE ASSAY IS NOW AVAILABLE FOR THE TB DIAGNOSTIC COMMUNITY TO INDEPENDENTLY EVALUATE EMERGING DIAGNOSTIC LATERAL FLOW ASSAYS FOR THE DETECTION OF URINARY LAM. FURTHER, PATH COMPLETED A FIELD PERFORMANCE EVALUATION STUDY OF A NEW PREECLAMPSIA TEST WITH PARTNERS IN GHANA. AN AFRICAN-BASED MANUFACTURER LAUNCHED THE PRODUCT IN LATE 2019. IT IS NOW BEING USED TO INFORM PATIENT CARE. FINALLY, IN COLLABORATION WITH A PRIVATE-SECTOR PARTNER, PATH WORKED TO DEVELOP A SEROTYPE-SPECIFIC URINE ANTIGEN DETECTION ASSAY ON A PLATFORM SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES. THE ASSAY PROVIDES HIGH-PERFORMANCE DETECTION ACROSS AN EXPANDED PANEL OF COMMON PNEUMOCOCCAL CONJUGATED VACCINE SEROTYPES. THIS ENHANCED CAPACITY INCREASES ITS UTILITY AS A TOOL FOR BOTH CLINICAL AND EPIDEMIOLOGIC STUDIES TO SUPPORT DEVELOPMENT OF A PNEUMONIA VACCINE.IMPACT LABS:PATH'S IMPACT LABS IN INDIA AND SOUTH AFRICA HELP ADVANCE THE MOST PROMISING HEALTH TECHNOLOGIES. THESE COUNTRIES HAVE RICH INNOVATION ECOSYSTEMS WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON DEVELOPING PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE.THE INDIA IMPACT LAB, A PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI, IS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY (MEDTECH) INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE. THE IMPACT LAB ALSO PARTNERS WITH TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES TO FURTHER DEVELOP THE INNOVATION ECOSYSTEM. IN 2019, THE IMPACT LAB BEGAN ENGAGEMENT WITH TEN SELECTED MEDTECH START-UPS UNDER THE QUEST FOR HEALTHCARE INNOVATIONS PROGRAM, A JOINT INITIATIVE WITH SOCIAL ALPHA. THE PROGRAM FEATURES A SYSTEMATIC, COHORT-BASED ENGAGEMENT MODEL, PROVIDING THE SELECTED START-UPS WITH CONTEXTUAL SUPPORT, GUIDANCE, AND MENTORSHIP IN PRODUCT DEVELOPMENT, CLINICAL EVIDENCE GENERATION, REGULATIONS, QUALITY MANAGEMENT, MARKET UNDERSTANDING, AND PROCUREMENT CHANNELS. ACTIVITIES INCLUDED A DEEP AND EXPANSIVE REQUIREMENT MAPPING FOR EACH START-UP AS WELL AS SUPPORT FOR THEIR CLINICAL VALIDATION JOURNEY AND GO-TO-MARKET NEEDS. THE IMPACT LAB CONDUCTED TWO CURATED CONVENINGS FOR THE COHORT: ONE WITH DOMAIN EXPERTS IN CLINICAL AND REGULATORY COMPLIANCE, THE OTHER WITH EXPERTS IN PUBLIC AND PRIVATE MEDICAL DEVICE TECHNOLOGY ASSESSMENT AND PROCUREMENT. ADDITIONALLY, THE IMPACT LAB DELIVERED FIVE FOCUSED KNOWLEDGE PLATFORMS, INCLUDING WORKSHOPS AND ROUNDTABLES FOR THE WIDER MEDTECH ECOSYSTEM. FOR THESE, THE IMPACT LAB ENGAGED WITH EXPERTS FROM NUMEROUS LARGE AND SMALL MEDTECH COMPANIES, PARTNER INCUBATORS, INDUSTRY, AND ACADEMIA, AS WELL AS KEY NATIONAL AND GLOBAL STAKEHOLDERS. THE KNOWLEDGE PLATFORMS COVERED A RANGE OF TOPICS-FROM TESTING AND CALIBRATING MEDICAL DEVICES TO MEDTECH REGULATIONS, LATE-STAGE PRODUCT DEVELOPMENT, AND MARKET ACCESS- AND INCLUDED ROUNDTABLE DISCUSSION OF PERTINENT ISSUES IN TB DETECTION, TREATMENT, AND ADHERENCE TO MEDICATION. THE IMPACT LAB, A CROSS-CUTTING INITIATIVE WITHIN PATH, PROVIDED SUPPORT TO PATH'S PROGRAM VERTICALS, FOR EXAMPLE IN THE DEVELOPMENT OF A MENSTRUAL HEALTH APPLICATION FOR WOMEN IN LOW- AND MIDDLE-INCOME COUNTRIES, DEVELOPMENT OF A TARGET PRODUCT PROFILE FOR MICROARRAY PATCHES FOR RABIES VACCINE DELIVERY, AND OPERATIONAL VALIDATION OF TRUENAT, A MOLECULAR DIAGNOSTIC DEVICE FOR DETECTION OF TB. THROUGH THE SOUTH AFRICA IMPACT LAB, PATH ACCELERATED OUR ASSISTANCE TO THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (SAMRC) THROUGH THE JOINT GLOBAL HEALTH INNOVATION ACCELERATOR (GHIA) PARTNERSHIP. GHIA, WHICH IS PRIMARILY FUNDED BY A GRANT FROM THE BILL & MELINDA GATES FOUNDATION TO SAMRC, CONTINUES TO SUPPORT THE DEVELOPMENT AND COMMERCIALIZATION OF MEDICAL TECHNOLOGIES DESIGNED FOR RESOURCE-LIMITED SETTINGS IN SOUTH AFRICA AND BEYOND. IN 2019, PATH HOSTED STAFF FROM SAMRC FOR A WEEKLONG EXCHANGE IN SEATTLE, WASHINGTON. THE FOCUS WAS ON SHARING INTERNAL PATH PROCESSES FOR TECHNOLOGY EVALUATION, PRODUCT DEVELOPMENT, AND GO-TO-MARKET STRATEGIES, AND IDENTIFYING AREAS OF SUPPORT ON CERTAIN GHIA PROJECTS. ADDITIONAL CAPACITY-BUILDING EFFORTS INCLUDED A "BOOTCAMP" SESSION IN CAPE TOWN TO DISCUSS PRODUCT INTRODUCTION TOPICS SUCH AS PROCUREMENT, MARKET SIZING, AND COUNTRY DOWN-SELECTION APPROACHES. TO INCREASE GHIA'S VISIBILITY, PATH AND SAMRC CO-WROTE AND PUBLISHED AN ARTICLE REFLECTING ON THE LAST FIVE YEARS.
(Code:
) (Expenses $
22,615,272
including grants of $
4,940,809
) (Revenue $
)
ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2019, PATH LED EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES, EUROPE, AND MULTILATERAL AGENCIES TO MAINTAIN AND STRENGTHEN WORK IN RESEARCH AND DEVELOPMENT (R&D), MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH SECURITY. OUR SUCCESSES IN 2019 INCLUDED PROTECTING KEY US GOVERNMENT FUNDING FOR OUR PRIORITY HEALTH AREAS AND SUCCESSFULLY INFLUENCING LANGUAGE CALLING FOR NEW R&D FUNDING AND STRONG REGULATORY SYSTEMS IN THE OUTCOME STATEMENT OF THE UNITED NATIONS HIGH-LEVEL MEETING ON UNIVERSAL HEALTH COVERAGE. WORKING WITH PARTNERS IN AFRICAN COUNTRIES, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. AMONG MANY ACHIEVEMENTS DURING 2019, IN THE DRC, A NATIONAL IMMUNIZATION FORUM WE ORGANIZED IN PARTNERSHIP WITH THE HEAD OF STATE LED TO AN UNPRECEDENTED COMMITMENT BY NATIONAL AND PROVINCIAL LEADERS TO IMPROVE ROUTINE IMMUNIZATION AND POLIO ERADICATION EFFORTS. IN UGANDA, PATH'S ONGOING IMMUNIZATION ADVOCACY RESULTED IN THE GOVERNMENT NEARLY DOUBLING ITS BUDGET FOR ROUTINE IMMUNIZATION. IN KENYA, YEARS OF ADVOCACY BY PATH RESULTED IN PASSAGE OF THE FIRST COMPREHENSIVE POLICY IDENTIFYING PRIORITIES FOR HEALTH R&D, AND IN SOUTH AFRICA, PATH'S ADVOCACY AND COALITION-BUILDING EFFORTS CONTINUED TO STRENGTHEN SUPPORT FOR HEALTH R&D.SPECIAL INITIATIVESPATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2019, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS. EACH HEALTH IMPACT TEAM HAS BEEN ONGOING FOR AT LEAST TWO YEARS, WORKING TO BUILD STRUCTURED COLLABORATION ACROSS PROGRAMS AND GEOGRAPHIES TO INCREASE PATH'S IMPACT.
4d
Other program services (Describe in Schedule O.)
(Expenses $
22,615,272
including grants of $
4,940,809
) (Revenue $
)
4e
Total program service expenses
257,713,007
Form
990
(2019)
Page 3
Form 990 (2019)
Page
3
Part IV
Checklist of Required Schedules
Yes
No
1
Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)?
If "Yes," complete Schedule A
.....................
1
Yes
2
Is the organization required to complete
Schedule B, Schedule of Contributors
(see instructions)?
...
2
Yes
3
Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office?
If "Yes," complete Schedule C,
Part I
.............
3
No
4
Section 501(c)(3) organizations.
Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year?
If "Yes," complete Schedule C,
Part II
.........
4
Yes
5
Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Revenue Procedure 98-19?
If "Yes," complete Schedule C,
Part III
..
5
No
6
Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts?
If "Yes," complete
Schedule D,
Part I
.........................
6
No
7
Did the organization receive or hold a conservation easement, including easements to preserve open space,
the environment, historic land areas, or historic structures?
If "Yes," complete Schedule D,
Part II
....
7
No
8
Did the organization maintain collections of works of art, historical treasures, or other similar assets?
If "Yes,"
complete Schedule D,
Part III
..............
8
No
9
Did the organization report an amount in
Part X
, line 21 for escrow or custodial account liability; serve as a custodian for amounts not listed in
Part X
; or provide credit counseling, debt management, credit repair, or debt negotiation services?
If "Yes," complete Schedule D,
Part IV
..............
9
No
10
Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi endowments?
If "Yes," complete Schedule D,
Part V
......
10
Yes
11
If the organization’s answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X as applicable.
a
Did the organization report an amount for land, buildings, and equipment in
Part X
, line 10?
If "Yes," complete
Schedule D,
Part VI
.
...................
11a
Yes
b
Did the organization report an amount for investments—other securities in
Part X
, line 12 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VII
.......
11b
No
c
Did the organization report an amount for investments—program related in
Part X
, line 13 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VIII
.......
11c
No
d
Did the organization report an amount for other assets in
Part X
, line 15 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part IX
............
11d
No
e
Did the organization report an amount for other liabilities in
Part X
, line 25?
If "Yes," complete Schedule D,
Part X
11e
No
f
Did the organization’s separate or consolidated financial statements for the tax year include a footnote that addresses the organization’s liability for uncertain tax positions under FIN 48 (ASC 740)?
If "Yes," complete Schedule D,
Part X
11f
No
12a
Did the organization obtain separate, independent audited financial statements for the tax year?
If "Yes," complete
Schedule D, Parts XI and XII
......................
12a
No
b
Was the organization included in consolidated, independent audited financial statements for the tax year?
If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional
12b
Yes
13
Is the organization a school described in section 170(b)(1)(A)(ii)?
If "Yes," complete Schedule E
13
No
14a
Did the organization maintain an office, employees, or agents outside of the United States?
.....
14a
Yes
b
Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more?
If "Yes," complete Schedule F, Parts I and IV
.........
14b
Yes
15
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization?
If “Yes,” complete Schedule F, Parts II and IV
.....
15
Yes
16
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals?
If “Yes,” complete Schedule F, Parts III and IV
...
16
No
17
Did the organization report a total of more than $15,000 of expenses for professional fundraising services on
Part IX
, column (A), lines 6 and 11e?
If "Yes," complete Schedule G,
Part I
(see instructions)
....
17
No
18
Did the organization report more than $15,000 total of fundraising event gross income and contributions on
Part VIII
, lines 1c and 8a?
If "Yes," complete Schedule G,
Part II
............
18
No
19
Did the organization report more than $15,000 of gross income from gaming activities on
Part VIII
, line 9a?
If "Yes," complete Schedule G,
Part III
...................
19
No
20a
Did the organization operate one or more hospital facilities?
If "Yes," complete Schedule H
....
20a
No
b
If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?
20b
21
Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on
Part IX
, column (A), line 1?
If “Yes,” complete Schedule I, Parts I and II
.....
21
Yes
Form
990
(2019)
Page 4
Form 990 (2019)
Page
4
Part IV
Checklist of Required Schedules
(continued)
Yes
No
22
Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on
Part IX
, column (A), line 2?
If “Yes,” complete Schedule I, Parts I and III
........
22
Yes
23
Did the organization answer "Yes" to
Part VII
, Section A, line 3, 4, or 5 about compensation of the organization’s current and former officers, directors, trustees, key employees, and highest compensated employees?
If "Yes," complete Schedule J
.......................
23
Yes
24a
Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002?
If “Yes,” answer lines 24b through 24d and complete Schedule K. If “No,” go to line 25a
...............
24a
No
b
Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?
...
24b
c
Did the organization maintain an escrow account other than a refunding escrow at any time during the year
to defease any tax-exempt bonds?
...............
24c
d
Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?
...
24d
25a
Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.
Did the organization engage in an excess benefit transaction with a disqualified person during the year?
If "Yes," complete Schedule L,
Part I
....
25a
No
b
Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization’s prior Forms 990 or 990-EZ?
If "Yes," complete Schedule L,
Part I
.......................
25b
No
26
Did the organization report any amount on Part X, line 5 or 22 for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons?
If "Yes," complete Schedule L,
Part II
...........
26
No
27
Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons?
If "Yes," complete
Schedule L,
Part III
.........................
27
No
28
Was the organization a party to a business transaction with one of the following parties (see Schedule L,
Part IV
instructions for applicable filing thresholds, conditions, and exceptions):
a
A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor?
If "Yes," complete Schedule L,
Part IV
......................
28a
No
b
A family member of any individual described in line 28a?
If "Yes," complete Schedule L,
Part IV
.....
28b
No
c
A 35% controlled entity of one or more individuals and/or organizations described in lines 28a or 28b?
If "Yes," complete Schedule L,
Part IV
.....................
28c
No
29
Did the organization receive more than $25,000 in non-cash contributions?
If "Yes," complete Schedule M
..
29
Yes
30
Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions?
If "Yes," complete Schedule M
.................
30
No
31
Did the organization liquidate, terminate, or dissolve and cease operations?
If "Yes," complete Schedule N,
Part I
31
No
32
Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets?
If "Yes," complete Schedule N,
Part II
........................
32
No
33
Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3?
If "Yes," complete Schedule R,
Part I
............
33
No
34
Was the organization related to any tax-exempt or taxable entity?
If "Yes," complete Schedule R,
Part II
, III, or IV, and
Part V
, line 1
.........................
34
Yes
35a
Did the organization have a controlled entity within the meaning of section 512(b)(13)?
35a
Yes
b
If ‘Yes’ to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)?
If "Yes," complete Schedule R,
Part V
, line 2
...
35b
Yes
36
Section 501(c)(3) organizations.
Did the organization make any transfers to an exempt non-charitable related organization?
If "Yes," complete Schedule R,
Part V
, line 2
.............
36
No
37
Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes?
If "Yes," complete Schedule R,
Part VI
37
No
38
Did the organization complete Schedule O and provide explanations in Schedule O for
Part VI
, lines 11b and 19?
Note.
All Form 990 filers are required to complete Schedule O.
............
38
Yes
Part V
Statements Regarding Other IRS Filings and Tax Compliance
Check if Schedule O contains a response or note to any line in this
Part V
...........
Yes
No
1a
Enter the number reported in Box 3 of Form 1096. Enter -0- if not applicable
..
1a
248
b
Enter the number of Forms W-2G included in line 1a. Enter -0- if not applicable
.
1b
0
c
Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?
..................
1c
Yes
Form
990
(2019)
Page 5
Form 990 (2019)
Page
5
Part V
Statements Regarding Other IRS Filings and Tax Compliance
(continued)
2a
Enter the number of employees reported on Form W-3, Transmittal of Wage and
Tax Statements, filed for the calendar year ending with or within the year covered by this return
..................
2a
737
b
If at least one is reported on line 2a, did the organization file all required federal employment tax returns?
Note.
If the sum of lines 1a and 2a is greater than 250, you may be required to e-file (see instructions)
2b
Yes
3a
Did the organization have unrelated business gross income of $1,000 or more during the year?
...
3a
No
b
If “Yes,” has it filed a Form 990-T for this year?
If “No” to line 3b, provide an explanation in Schedule O
...
3b
4a
At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?
..
4a
Yes
b
If "Yes," enter the name of the foreign country:
BE
,
CH
,
CG
,
ET
,
GH
,
IN
,
KE
,
BM
,
MZ
,
PE
,
SG
,
SF
,
SZ
,
TZ
,
UG
,
UK
,
UP
,
VM
,
ZA
See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).
5a
Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?
..
5a
No
b
Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?
5b
No
c
If "Yes," to line 5a or 5b, did the organization file Form 8886-T?
............
5c
6a
Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?
...
6a
No
b
If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?
......................
6b
7
Organizations that may receive deductible contributions under section 170(c).
a
Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?
....................
7a
No
b
If "Yes," did the organization notify the donor of the value of the goods or services provided?
.....
7b
c
Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?
.........................
7c
No
d
If "Yes," indicate the number of Forms 8282 filed during the year
....
7d
e
Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?
7e
No
f
Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?
..
7f
No
g
If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?
......................
7g
h
If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?
..........................
7h
8
Sponsoring organizations maintaining donor advised funds.
Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?
........
8
9
Sponsoring organizations maintaining donor advised funds.
a
Did the sponsoring organization make any taxable distributions under section 4966?
........
9a
b
Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?
...
9b
10
Section 501(c)(7) organizations.
Enter:
a
Initiation fees and capital contributions included on
Part VIII
, line 12
...
10a
b
Gross receipts, included on Form 990,
Part VIII
, line 12, for public use of club facilities
10b
11
Section 501(c)(12) organizations.
Enter:
a
Gross income from members or shareholders
.........
11a
b
Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them.)
..........
11b
12a
Section 4947(a)(1) non-exempt charitable trusts.
Is the organization filing Form 990 in lieu of Form 1041?
12a
b
If "Yes," enter the amount of tax-exempt interest received or accrued during the year.
12b
13
Section 501(c)(29) qualified nonprofit health insurance issuers.
a
Is the organization licensed to issue qualified health plans in more than one state?
.........
Note.
See the instructions for additional information the organization must report on Schedule O.
13a
b
Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans
....
13b
c
Enter the amount of reserves on hand
............
13c
14a
Did the organization receive any payments for indoor tanning services during the tax year?
.....
14a
No
b
If "Yes," has it filed a Form 720 to report these payments?
If "No," provide an explanation in Schedule O
..
14b
15
Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year?
....................
If "Yes," see instructions and file Form 4720, Schedule N.
15
No
16
Is the organization an educational institution subject to the section 4968 excise tax on net investment income?
..
If "Yes," complete Form 4720, Schedule O.
16
No
Form
990
(2019)
Page 6
Form 990 (2019)
Page
6
Part VI
Governance, Management, and Disclosure
For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines
8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.
Check if Schedule O contains a response or note to any line in this
Part VI
..............
Section A. Governing Body and Management
Yes
No
1a
Enter the number of voting members of the governing body at the end of the tax year
1a
15
If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.
b
Enter the number of voting members included in line 1a, above, who are independent
1b
15
2
Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?
.................
2
No
3
Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person?
.
3
No
4
Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?
.
4
No
5
Did the organization become aware during the year of a significant diversion of the organization’s assets?
.
5
No
6
Did the organization have members or stockholders?
................
6
No
7a
Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?
....................
7a
No
b
Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?
...................
7b
No
8
Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:
a
The governing body?
.......................
8a
Yes
b
Each committee with authority to act on behalf of the governing body?
............
8b
Yes
9
Is there any officer, director, trustee, or key employee listed in
Part VII
, Section A, who cannot be reached at the organization’s mailing address?
If "Yes," provide the names and addresses in Schedule O
.......
9
No
Section B. Policies
(
This Section B requests information about policies not required by the Internal Revenue Code.
)
Yes
No
10a
Did the organization have local chapters, branches, or affiliates?
............
10a
No
b
If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?
10b
11a
Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?
............................
11a
Yes
b
Describe in Schedule O the process, if any, used by the organization to review this Form 990.
.....
12a
Did the organization have a written conflict of interest policy?
If "No," go to line 13
.......
12a
Yes
b
Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?
..........................
12b
Yes
c
Did the organization regularly and consistently monitor and enforce compliance with the policy?
If "Yes," describe in Schedule O how this was done
...................
12c
Yes
13
Did the organization have a written whistleblower policy?
...............
13
Yes
14
Did the organization have a written document retention and destruction policy?
.........
14
Yes
15
Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?
a
The organization’s CEO, Executive Director, or top management official
...........
15a
Yes
b
Other officers or key employees of the organization
................
15b
Yes
If "Yes" to line 15a or 15b, describe the process in Schedule O (see instructions).
16a
Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?
......................
16a
No
b
If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization’s exempt status with respect to such arrangements?
............
16b
Section C. Disclosure
17
List the states with which a copy of this Form 990 is required to be filed
AL
,
AR
,
CA
,
CT
,
FL
,
IL
,
KS
,
KY
,
MA
,
MD
,
MI
,
MN
,
MS
,
NC
,
NH
,
NJ
,
NM
,
NY
,
OK
,
OR
,
PA
,
RI
,
SC
,
TN
,
UT
,
VA
,
WI
,
WV
18
Section 6104 requires an organization to make its Form 1023 (or 1024-A if applicable), 990, and 990-T (501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
Own website
Another's website
Upon request
Other (explain in Schedule O)
19
Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20
State the name, address, and telephone number of the person who possesses the organization's books and records:
BRIAN NEVILLE VP ACCOUNTINGFINANCIAL OPERATIONS
2201 WESTLAKE AVE SUITE 200
SEATTLE
,
WA
98121
(206) 285-3500
Form
990
(2019)
Page 7
Form 990 (2019)
Page
7
Part VII
Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors
Check if Schedule O contains a response or note to any line in this
Part VII
..............
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
1a
Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization’s tax year.
List all of the organization’s
current
officers, directors, trustees (whether individuals or organizations), regardless of amount
of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
List all of the organization’s
current
key employees, if any. See instructions for definition of "key employee."
List the organization’s five
current
highest compensated employees (other than an officer, director, trustee or key employee)
who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than $100,000 from the
organization and any related organizations.
List all of the organization’s
former
officers, key employees, or highest compensated employees who received more than $100,000
of reportable compensation from the organization and any related organizations.
List all of the organization’s
former directors or trustees
that received, in the capacity as a former director or trustee of the
organization, more than $10,000 of reportable compensation from the organization and any related organizations.
See instructions for the order in which to list the persons above.
Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC)
(F)
Estimated amount of other compensation from the organization and related organizations
(1)
DAVID KING
......................................................................
CHAIR
2.00
.................
X
X
0
0
0
(2)
BETH GALETTI
......................................................................
VICE CHAIR
2.00
.................
X
X
0
0
0
(3)
YEHONG ZHANG
......................................................................
SECRETARY
2.00
.................
X
X
0
0
0
(4)
BRUCE MCNAMER
......................................................................
TREASURER
2.00
.................
X
X
0
0
0
(5)
FELIX OLALE
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(6)
JO ADDY
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(7)
IREENA VITTAL
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(8)
DEANNA OPPENHEIMER
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(9)
JOHN-ARNE ROTTINGEN
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(10)
JOEL HOLSINGER
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(11)
HELENA WAYTH
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(12)
SANFORD MELZER
......................................................................
DIRECTOR
2.00
.................
X
0
0
0
(13)
ABAYOMI SULE
......................................................................
DIRECTOR (BEGAN 6/2019)
2.00
.................
X
0
0
0
(14)
LISA ANDERSON
......................................................................
DIRECTOR (BEGAN 6/2019)
2.00
.................
X
0
0
0
(15)
RACHEL SIBANDE
......................................................................
DIRECTOR (BEGAN 6/2019)
2.00
.................
X
0
0
0
(16)
STEPHEN BROWN DAVIS
......................................................................
PRESIDENT AND CEO
39.00
.................
1.00
X
560,672
0
64,002
(17)
OLIVIA D POLIUS
......................................................................
CHIEF FINANCIAL OFFICER
39.00
.................
1.00
X
348,833
0
31,967
Form
990
(2019)
Page 8
Form 990 (2019)
Page
8
Part VII
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
(continued)
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC)
(F)
Estimated amount of other compensation from the organization and related organizations
(18)
JERRY KUO
........................................................................
CHIEF OF STRATEGIC FINANCE
39.00
.......................
1.00
X
215,587
0
55,953
(19)
BRIAN N NEVILLE
........................................................................
CHIEF OF ACCOUNTING
39.00
.......................
1.00
X
223,677
0
34,710
(20)
PRAVEEN RAJA
........................................................................
CHIEF OPERATING OFFICER
39.00
.......................
1.00
X
408,540
0
39,837
(21)
DAVID C KASLOW
........................................................................
VP - ESSENTIAL MEDICNES
39.00
.......................
1.00
X
383,540
0
66,181
(22)
JEFFREY D BERNSON
........................................................................
VP - TECH, ANALYTICS, & MRKT INNOV.
40.00
.......................
X
373,374
0
57,347
(23)
DAVID W FLEMING
........................................................................
VP - PUBLIC HEALTH
40.00
.......................
X
301,683
0
48,312
(24)
ELAINE L GIBBONS
........................................................................
VP - GLOBAL ENGAGEMENT
40.00
.......................
X
250,039
0
72,215
(25)
MOLLI M BARNES
........................................................................
CHIEF PEOPLE OFFICER
40.00
.......................
X
216,837
0
47,872
(26)
ERICA JANE SESSLE
........................................................................
CHIEF OF STAFF
40.00
.......................
X
214,896
0
36,881
(27)
SABRINA L POWERS
........................................................................
GENERAL COUNSEL
40.00
.......................
X
161,635
0
31,739
(28)
TRAD M HATTON
........................................................................
COUNTRY DIRECTOR
40.00
.......................
X
333,412
0
49,783
(29)
JAMES B MCKENNA
........................................................................
DEPUTY DIRECTOR
40.00
.......................
X
290,281
0
77,625
(30)
ASHLEY J BIRKETT
........................................................................
GLOBAL HEAD, MALARIA VACCINES
40.00
.......................
X
310,040
0
59,402
(31)
BRUCE LAMONT INNIS
........................................................................
GLOBAL HEAD, RESPIRATORY INFECTIONS
40.00
.......................
X
320,624
0
32,892
(32)
JOHN O KONZ
........................................................................
GLOBAL HEAD, FINANCIAL MANAGEMENT
40.00
.......................
X
312,968
0
61,168
1b
Sub-Total
................
c
Total from continuation sheets to
Part VII
, Section A
....
d
Total (add lines 1b and 1c)
...........
5,226,638
0
867,886
2
Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization
318
Yes
No
3
Did the organization list any
former
officer, director or trustee, key employee, or highest compensated employee on line 1a?
If "Yes," complete Schedule J for such individual
..............
3
No
4
For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000?
If "Yes," complete Schedule J for such
individual
...........................
4
Yes
5
Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization?
If "Yes," complete Schedule J for such person
........
5
No
Section B. Independent Contractors
1
Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization’s tax year.
(A)
Name and business address
(B)
Description of services
(C)
Compensation
WMBE PAYROLLING DBA TARGETCW
9475 CHESAPEAKE DR
SAN DIEGO
,
CA
92123
GENERAL CONTRACTOR
726,012
AIRCRUISE TRAVELS PVT LTD
C 101 - 102 LAJPAT NAGAR 1
NEW DELHI
110024
IN
TRAVEL SERVICES
522,166
UNIT4 BUSINESS SOFTWARE INC
3 BURLINGTON WOODS SUITE 201
BURLINGTON
,
MA
01803
SYSTEMS CONTRACTOR
414,490
RANDSTAD INDIA PVT LTD
SUIT NO 001 002 COPIA
NEW DELHI
110025
IN
STAFFING SERVICES
391,145
CLARK NUBER & CO PS
10900 NE 4TH ST SUITE 1400
BELLEVUE
,
WA
98004
ACCOUNTING SERVICES
375,309
2
Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization
46
Form
990
(2019)
Page 9
Form 990 (2019)
Page
9
Part VIII
Statement of Revenue
Check if Schedule O contains a response or note to any line in this
Part VIII
.............
(A)
Total revenue
(B)
Related or
exempt
function
revenue
(C)
Unrelated
business
revenue
(D)
Revenue
excluded from
tax under sections
512 - 514
1a
Federated campaigns
..
1a
b
Membership dues
..
1b
c
Fundraising events
..
1c
d
Related organizations
1d
4,265,711
e
Government grants (contributions)
1e
106,320,456
f
All other contributions, gifts, grants, and similar amounts not included above
1f
176,222,378
g
Noncash contributions included in lines 1a - 1f:$
1g
4,343,453
h Total.
Add lines 1a-1f
.......
286,808,545
Business Code
2a
CONSULTANCIES
541900
2,038
2,038
b
c
d
e
f
All other program service revenue.
g
Total.
Add lines 2a–2f
.....
2,038
3
Investment income (including dividends, interest, and other
similar amounts)
......
6,310,221
6,310,221
4
Income from investment of tax-exempt bond proceeds
5
Royalties
...........
(ii) Personal
(i) Real
6a
Gross rents
6a
b
Less: rental expenses
6b
c
Rental income or (loss)
6c
d
Net rental income or (loss)
.......
(ii) Other
(i) Securities
7a
Gross amount from sales of assets other than inventory
38,000
89,753,987
7a
b
Less: cost or other basis and sales expenses
188,547
89,190,233
7b
c
Gain or (loss)
-150,547
563,754
7c
d
Net gain or (loss)
.........
413,207
413,207
8a
Gross income from fundraising events (not including $
of contributions reported on line 1c).
See
Part IV
, line 18
....
8a
b
Less: direct expenses
...
8b
c
Net income or (loss) from fundraising events
..
9a
Gross income from gaming activities.
See
Part IV
, line 19
...
9a
b
Less: direct expenses
...
9b
c
Net income or (loss) from gaming activities
..
10a
Gross sales of inventory, less
returns and allowances
..
10a
b
Less: cost of goods sold
..
10b
c
Net income or (loss) from sales of inventory
..
Business Code
Miscellaneous Revenue
11a
OTHER
900099
806,343
806,343
b
REIMBURSEMENTS
900099
30,527
30,527
c
d
All other revenue
....
e
Total.
Add lines 11a–11d
......
836,870
12
Total revenue.
See instructions
.....
294,370,881
2,038
0
7,560,298
Form
990
(2019)
Page 10
Form 990 (2019)
Page
10
Part IX
Statement of Functional Expenses
Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).
Check if Schedule O contains a response or note to any line in this
Part IX
..............
Do not include amounts reported on lines 6b,
7b, 8b, 9b, and 10b of
Part VIII
.
(A)
Total expenses
(B)
Program service
expenses
(C)
Management and
general expenses
(D)
Fundraising
expenses
1
Grants and other assistance to domestic organizations and domestic governments. See
Part IV
, line 21
....
16,151,505
16,151,505
2
Grants and other assistance to domestic individuals. See
Part IV
, line 22
...........
10,313
10,313
3
Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See
Part IV
, lines 15 and 16.
.............
39,457,262
39,457,262
4
Benefits paid to or for members
.......
5
Compensation of current officers, directors, trustees, and key employees
...........
4,246,329
659,952
3,555,676
30,701
6
Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)
.........
7
Other salaries and wages
........
95,165,062
85,092,916
8,828,907
1,243,239
8
Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)
....
10,334,465
8,600,526
1,597,257
136,682
9
Other employee benefits
.......
15,489,969
13,144,164
2,160,891
184,914
10
Payroll taxes
...........
6,354,673
5,288,484
982,144
84,045
11
Fees for services (non-employees):
a
Management
......
b
Legal
.........
551,399
374,203
177,196
c
Accounting
...........
483,910
91,666
392,244
d
Lobbying
...........
2,986
2,986
e
Professional fundraising services.
See
Part IV
, line 17
f
Investment management fees
......
186,964
186,964
g
Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)
15,623,175
11,637,627
3,756,218
229,330
12
Advertising and promotion
....
198,936
179,102
5,043
14,791
13
Office expenses
.......
6,900,163
5,434,596
1,382,874
82,693
14
Information technology
......
1,363,777
450,053
899,342
14,382
15
Royalties
..
46,984
46,984
16
Occupancy
...........
12,090,090
228,951
11,861,139
17
Travel
............
18,810,123
17,257,403
1,525,961
26,759
18
Payments of travel or entertainment expenses for any federal, state, or local public officials
.
19
Conferences, conventions, and meetings
....
8,225,745
8,102,741
66,093
56,911
20
Interest
...........
1,901
2
1,899
21
Payments to affiliates
.......
22
Depreciation, depletion, and amortization
..
3,202,950
12,403
3,190,547
23
Insurance
...
669,187
212,403
456,784
24
Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a
SUBCONTRACTORS
25,505,228
25,366,038
139,190
b
EQUIP RENT & MAINT
3,622,319
2,157,809
1,461,681
2,829
c
DIRECT AID TO BENEFICIA
3,034,623
3,034,623
d
FACILITIES ALLOC
0
13,042,418
-13,264,007
221,589
e
All other expenses
4,578,801
1,675,877
2,552,439
350,485
25
Total functional expenses.
Add lines 1 through 24e
292,308,839
257,713,007
31,916,482
2,679,350
26
Joint costs.
Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation.
Check here
if following SOP 98-2 (ASC 958-720).
Form
990
(2019)
Page 11
Form 990 (2019)
Page
11
Part X
Balance Sheet
Check if Schedule O contains a response or note to any line in this
Part IX
..............
(A)
Beginning of year
(B)
End of year
1
Cash–non-interest-bearing
........
7,576,050
1
8,845,877
2
Savings and temporary cash investments
.........
14,017,223
2
17,517,988
3
Pledges and grants receivable, net
......
35,571,476
3
44,215,907
4
Accounts receivable, net
.............
10,652,789
4
16,731,594
5
Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.......
5
6
Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)
...
6
7
Notes and loans receivable, net
...........
7
8
Inventories for sale or use
............
8
9
Prepaid expenses and deferred charges
......
5,307,245
9
7,170,218
10a
Land, buildings, and equipment: cost or other basis. Complete
Part VI
of Schedule D
10a
36,971,911
b
Less: accumulated depreciation
10b
26,980,281
11,047,905
10c
9,991,630
11
Investments—publicly traded securities
.
153,328,545
11
138,590,941
12
Investments—other securities. See
Part IV
, line 11
.....
12
13
Investments—program-related. See
Part IV
, line 11
..
13
14
Intangible assets
...............
14
15
Other assets. See
Part IV
, line 11
...........
15
16
Total assets.
Add lines 1 through 15 (must equal line 33)
...
237,501,233
16
243,064,155
17
Accounts payable and accrued expenses
.....
202,736,996
17
204,045,574
18
Grants payable
...
18
19
Deferred revenue
.........
19
20
Tax-exempt bond liabilities
.........
20
21
Escrow or custodial account liability.
Complete
Part IV
of Schedule D
21
22
Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.........
22
23
Secured mortgages and notes payable to unrelated third parties
..
194,878
23
24
Unsecured notes and loans payable to unrelated third parties
..
24
25
Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24).
Complete
Part X
of Schedule D
25
26
Total liabilities.
Add lines 17 through 25
..
202,931,874
26
204,045,574
Organizations that follow FASB ASC 958,
check here
and complete lines 27, 28, 32, and 33.
27
Net assets without donor restrictions
..........
19,811,400
27
20,518,990
28
Net assets with donor restrictions
...........
14,757,959
28
18,499,591
Organizations that do not follow FASB ASC 958,
check here
and complete lines 29 through 33.
29
Capital stock or trust principal, or current funds
.....
29
30
Paid-in or capital surplus, or land, building or equipment fund
...
30
31
Retained earnings, endowment, accumulated income, or other funds
31
32
Total net assets or fund balances
...........
34,569,359
32
39,018,581
33
Total liabilities and net assets/fund balances
........
237,501,233
33
243,064,155
Form
990
(2019)
Page 12
Form 990 (2019)
Page
12
Part XI
Reconcilliation of Net Assets
Check if Schedule O contains a response or note to any line in this
Part XI
..............
1
Total revenue (must equal
Part VIII
, column (A), line 12)
............
1
294,370,881
2
Total expenses (must equal
Part IX
, column (A), line 25)
............
2
292,308,839
3
Revenue less expenses. Subtract line 2 from line 1
..............
3
2,062,042
4
Net assets or fund balances at beginning of year (must equal
Part X
, line 32, column (A))
..
4
34,569,359
5
Net unrealized gains (losses) on investments
...............
5
2,387,180
6
Donated services and use of facilities
.................
6
7
Investment expenses
.....................
7
8
Prior period adjustments
.....................
8
9
Other changes in net assets or fund balances (explain in Schedule O)
........
9
0
10
Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal
Part X
, line 32, column (B))
10
39,018,581
Part XII
Financial Statements and Reporting
Check if Schedule O contains a response or note to any line in this
Part XII
.............
Yes
No
1
Accounting method used to prepare the Form 990:
Cash
Accrual
Other
If the organization changed its method of accounting from a prior year or checked "Other," explain in
Schedule O.
2a
Were the organization’s financial statements compiled or reviewed by an independent accountant?
2a
No
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
b
Were the organization’s financial statements audited by an independent accountant?
2b
Yes
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
c
If "Yes," to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight
of the audit, review, or compilation of its financial statements and selection of an independent accountant?
2c
Yes
If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.
3a
As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?
3a
Yes
b
If "Yes," did the organization undergo the required audit or audits?
If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.
3b
Yes
Form
990
(2019)
Form 990 (2019)
Additional Data
Software ID:
Software Version:
Form 990, Special Condition Description:
Special Condition Description